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OBJECTIVES We sought to determine the effects of vasopressin and saline placebo in comparison with
epinephrine on neurologic recovery and possible cerebral pathology in an established porcine
model of prolonged cardiopulmonary resuscitation (CPR).
BACKGROUND It is unknown whether increased cerebral blood flow during CPR with vasopressin is
beneficial with regard to neurologic recovery or detrimental owing to complications such as
cerebral edema after return of spontaneous circulation.
METHODS After 4 min of cardiac arrest, followed by 3 min of basic life support CPR, 17 animals were
randomly assigned to receive every 5 min either vasopressin (0.4, 0.4 and 0.8 U/kg; n 5 6),
epinephrine (45, 45 and 200 mg/kg; n 5 6) or saline placebo (n 5 5). The mean value 6 SEM
of aortic diastolic pressure was significantly (p , 0.05) higher 90 s after each of three
vasopressin versus epinephrine versus saline placebo injections (60 6 3 vs. 45 6 3 vs. 29 6
2 mm Hg; 49 6 5 vs. 27 6 3 vs. 23 6 1 mm Hg; and 50 6 6 vs. 21 6 3 vs. 16 6 3 mm Hg,
respectively). After 22 min of cardiac arrest, including 18 min of CPR, defibrillation was
attempted to achieve return of spontaneous circulation.
RESULTS All the pigs that received epinephrine and saline placebo died, whereas all pigs on vasopressin
survived (p , 0.05). Neurologic evaluation 24 h after successful resuscitation revealed only an
unsteady gait in all vasopressin-treated animals; after 96 h, magnetic resonance imaging
revealed no cerebral pathology.
CONCLUSIONS During prolonged CPR, repeated vasopressin administration, but not epinephrine or saline
placebo, ensured long-term survival with full neurologic recovery and no cerebral pathology
in this porcine CPR model. (J Am Coll Cardiol 2000;35:527–33) © 2000 by the American
College of Cardiology
Morbidity and mortality after successful cardiopulmonary
resuscitation (CPR) largely depends on recovery of neuro-
logic function (1). Accordingly, efficiency of an intervention
during CPR has to be judged with regard to its effects on
neurologic outcome. Although both the American Heart
Association (2) and the European Resuscitation Council (3)
recommend epinephrine during CPR, this drug is being
discussed controversially. For example, CPR laboratory
studies with epinephrine revealed increased myocardial ox-
ygen consumption (4), ventilation-perfusion defect (5) dur-
ing CPR, incidence of ventricular arrhythmias (6) and
myocardial dysfunction (7) in the postresuscitation phase. In
one clinical study, epinephrine did not result in better
short-term survival or hospital discharge rate as compared
with saline placebo (8). Moreover, high dose epinephrine
did not improve hospital discharge rates in several large
multicenter clinical trials (9–11).
In animal studies of short (12) and prolonged (13) cardiac
arrest, vasopressin resulted in significantly higher vital organ
blood flow and cerebral oxygen delivery (14) than did epineph-
rine. In some patients, vasopressin resulted in return of spon-
taneous circulation after unsuccessful prolonged CPR with
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epinephrine (15). When compared with epinephrine, vaso-
pressin significantly improved 24-h survival rate in a small
study of patients (n 5 40) with ventricular fibrillation (16).
It is unknown whether increased cerebral blood flow
during CPR with vasopressin is beneficial with regards to
neurologic recovery or detrimental owing to fatal complica-
tions such as cerebral edema after return of spontaneous
circulation. Although a Glasgow coma score rating was
performed after successful CPR with vasopressin versus
epinephrine in preliminary clinical studies (15,16), unfortu-
nately the results could not be attributed to a single CPR
intervention owing to many confounding variables. In
addition, even full neurologic recovery after successful re-
suscitation from cardiac arrest does not prove the absence of
cerebral pathology. Accordingly, the purpose of the present
study was to evaluate the effects of vasopressin versus
epinephrine versus saline placebo given during prolonged
CPR on neurologic outcome with subsequent cerebral
magnetic resonance imaging (MRI).
METHODS
Surgical preparation and measurements. This project was
approved by the Austrian Federal Animal Investigational
Committee, and the animals were managed in accordance
with the Institutional Guidelines of the American Physio-
logical Society and “Position of the American Heart Asso-
ciation on Research Animal Use,” adopted by the Associa-
tion in November 1984. Animal care and use were
performed by qualified individuals supervised by veterinar-
ians, and all facilities and transportation complied with
current legal requirements and guidelines. Anesthesia was
used in all surgical interventions; all unnecessary suffering
was avoided; and research was terminated if unnecessary
pain or fear resulted. Our animal facilities meet the stan-
dards of the American Association for Accreditation of
Laboratory Animal Care. This study was performed, ac-
cording to Utstein-style guidelines (17), on 17 healthy swine
(12 to 16 weeks old, 30 to 40 kg). The animals were fasted
overnight, but had free access to water. The pigs were
premedicated with azaperone (4 mg/kg intramuscularly
[IM]) and atropine (0.1 mg/kg IM) 1 h before the opera-
tion, and anesthesia was induced with thiopental (7 to
15 mg/kg intravenously [IV]). After intubation, the pigs
were mechanically ventilated (Draeger, Lu¨beck, Germany)
with 100% oxygen at 20 breaths/min and with a tidal
volume adjusted to maintain normocapnia. Anesthesia was
maintained with propofol (6 to 8 mg/kg per h) and
piritramid (30 mg). Muscle paralysis was achieved with
8 mg pancuronium after intubation, and subsequently as
needed. Ringer’s solution (6 ml/kg per h) and a 3% gelatine
solution (4 ml/kg per h) was administered in the preparation
phase and in the postresuscitation phase. A standard lead II
electrocardiogram (ECG) was used to monitor cardiac
rhythm; depth of anesthesia was judged according to blood
pressure, heart rate and electroencephalography (Engstro¨m,
Munich, Germany). If cardiovascular variables or electroen-
cephalography indicated a reduced depth of anesthesia,
additional propofol and piritramid was given. Body temper-
ature was maintained between 38°C and 39°C. A 5F
catheter was advanced into the descending aorta through
femoral cutdown in an aseptic manner for withdrawal of
blood samples and measurement of arterial blood pressure.
Blood pressure was measured with a saline-filled catheter
attached to a pressure transducer (Hewlett Packard, Bo¨blin-
gen, Germany) that was calibrated to atmospheric pressure
at the level of the right atrium; pressure tracings were
recorded with a data acquisition system (Dewetron, Graz,
Austria). Blood gases were measured with a blood gas
analyzer (Chiron, Walpole, Massachusetts); end-tidal car-
bon dioxide was measured using an infrared absorption
analyzer (Siemens, Erlangen, Germany).
Experimental protocol. Fifteen minutes before cardiac
arrest, 5,000 U heparin IV was administered to prevent
intracardiac clot formation; 15 mg piritramid and 8 mg
pancuronium were given; and prearrest variables were mea-
sured. A 50-Hz, 60-V alternating current was then applied
through two subcutaneous needle electrodes to induce
ventricular fibrillation. Cardiac arrest was defined as the
point at which aortic pressure decreased profoundly to
hydrostatic pressure, and the ECG showed ventricular
fibrillation; ventilation was stopped at that point. After
4 min of untreated ventricular fibrillation, CPR was per-
formed manually, and mechanical ventilation was resumed
with the same setting as before induction of cardiac arrest.
Chest compressions were always performed by the same
investigator at a rate of 80 beats/min guided by acoustical
audiotones, with no knowledge of hemodynamic and end-
tidal carbon dioxide monitor tracings.
Seventeen animals were randomly assigned to receive
either vasopressin (n 5 6), epinephrine (n 5 6) or saline
placebo (n 5 5) after 3, 8 and 13 min of CPR, respectively.
The first two drug injections were optimal doses (0.4 U/kg
vasopressin vs. 45 mg/kg epinephrine) (12,18), followed by
maximal effective doses (0.8 U/kg vasopressin vs. 200 mg/kg
epinephrine) (12,19). All drugs were diluted to 10 ml with
normal saline and injected into an ear vein, which was
followed by 20 ml saline flush (investigators had no knowl-
edge of the drugs). After 22 min of cardiac arrest, up to five
countershocks were administered with an energy of 3, 4 and
6 J/kg. If asystole or pulseless electrical activity was present
after defibrillation, the experiment was terminated. Return
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of spontaneous circulation was defined as an unassisted
pulse with a systolic arterial pressure of $80 mm Hg, lasting
for at least 5 min. When indicated, surviving animals received
infusions of dopamine, phenylephrine, nitroglycerin, lidocaine,
nalbuphine and amiodarone. When blood pressure, acid-base
and metabolic function indicated a normalization, the pigs
were weaned from the ventilator and extubated. The animals
were then returned to their cages; neurologic evaluation ac-
cording to the Neurologic Deficit Score (20) was performed 24
and 96 h after return of spontaneous circulation by a neurol-
ogist who had no knowledge of the study drug.
Four days after successful CPR, surviving animals under-
went MRI while being ventilated under general anesthesia.
A 1.5-tesla whole-body magnetic resonance scanner (Mag-
netom, Siemens) and a circular polarized volume coil with
an internal diameter of 30 cm (CP head coil) were used.
Fast spin echo T2-weighted sequences (TR 5,000 ms, TE
120 ms, matrix 256 3 256, slice thickness 3 mm) were
applied in transverse planes with a field of view of 140 mm
and in coronal planes with a field of view of 160 mm. Also,
a sagittal T1-weighted sequence (TR 650 ms, TE 14 ms,
matrix 256 3 256, slice thickness 4 mm, field of view
200 mm) was performed. The films were assessed indepen-
dently by two neuroradiologists who had no knowledge of
the drug therapy for cortical and subcortical edema, intra-
parenchymal hemorrhage, ischemic brain lesions and cere-
bral infarction. After MRI, the pigs were killed and nec-
ropsied to verify the correct positioning of the catheters and
injuries to the rib cage.
Statistical analysis. Comparability of baseline data was
tested using a t test for continuous variables. One-way
analysis of variance was used to determine statistical signif-
icance between groups and were corrected with the Bonfer-
roni method for multiple comparisons. Survival rates were
analyzed using the Fisher exact test. A two-tailed p value
,0.05 was considered statistically significant.
RESULTS
Before induction of ventricular fibrillation and before drug
administration during CPR, there were no differences in
weight, hemodynamic variables and blood gases between
the groups. Pigs treated during CPR with vasopressin had
significantly (p , 0.05) higher aortic diastolic pressure than
did pigs given epinephrine and saline placebo (Fig. 1).
End-tidal carbon dioxide data revealed declining values in
both the epinephrine and saline placebo groups, but only
slightly in the vasopressin group (Table 1). All vasopressin-
treated pigs had return of spontaneous circulation after
1.8 6 0.3 countershocks and were extubated 228 6 37 min
later; whereas no pigs given epinephrine or saline placebo
had return of spontaneous circulation (p , 0.05 vs. vaso-
pressin). Neurologic evaluation 24 h after successful CPR
revealed an unsteady gait in all vasopressin-treated animals
with a neurologic deficit score of 10/400; after 96 h, the
neurologic deficit score in all animals was 0/400. All
vasopressin-treated animals were drinking and eating one
day after successful CPR and had normal levels of con-
sciousness, respiratory pattern and behavior. Cerebral MRI
revealed no cortical or subcortical edema, intraparenchymal
hemorrhage, ischemic lesions or infarction in any animal
(Fig. 2, 3). Necropsy confirmed appropriate catheter posi-
tions and revealed no injuries to the rib cage or intra-
abdominal or intrathoracic organs in all animals.
DISCUSSION
Clinical trials require huge efforts; animal studies give
rapid answers. It is extremely difficult to determine the
effects of a drug given during CPR on neurologic recovery
owing to confounding variables. For example, a given
patient group differs significantly owing to past medical
history, standard of life, age, race, cardiac rhythm at collapse
and location of cardiac arrest (21,22). Second, the health
care system itself may affect CPR outcome fundamentally
owing to differences in emergency medical services, response
times, intensive care unit management and access to diag-
nostic technology (23,24). To detect a significant increase in
hospital discharge rates or neurologic recovery, or both,
using a new pharmacologic CPR intervention, ;15,000
patients, several years and hundreds of millions of U.S.
dollars would be necessary—a trial that would be signifi-
cantly larger than the Framingham Heart studies with
typically ;3,000 (25) to ;5,000 patients (26). In contrast,
an animal model is able to rapidly determine the role of a
new drug given during CPR on neurologic recovery with
reasonable financial expenses. Although anesthetized and
paralyzed animals may have a different blood pressure
response to vasopressors during CPR than nonanesthetized,
nonparalyzed humans with sudden cardiac arrest, similar
results were found in both animal studies and clinical studies
with regard to vasopressin response (12–16,27,28); further,
there is simply no alternative for anesthetized animals to
control confounding variables during a CPR experiment
(17). In our experiment, vasopressin, but not epinephrine or
saline placebo, was able to maintain aortic diastolic pressure
during prolonged CPR above a threshold of 30 to
40 mm Hg, which is necessary for successful defibrillation
(29). Accordingly, all animals given epinephrine and saline
placebo died, whereas all pigs treated with vasopressin
survived 96 h with full neurologic recovery (p , 0.05), when
the experiment was terminated after cerebral MRI.
Epinephrine during CPR may cause adverse effects.
Although epinephrine improved coronary perfusion pres-
sure significantly as compared with saline placebo after the
first drug administration in our pigs, this standard vasopres-
sor (2,3) for CPR had no better effects than did saline
placebo after the second and third drug administrations.
Interestingly, end-tidal carbon dioxide before defibrillation
was the lowest in the epinephrine group, indicating a critical
reduction in pulmonary blood flow and therefore cardiac
output during CPR (30). This is similar to a large clinical
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trial in which epinephrine did not result in better short-term
survival or hospital discharge rate as compared with saline
placebo (8). A possible explanation for the failure of
epinephrine to maintain vital organ blood flow during CPR
may be, in part, an epinephrine-fueled cardiac oxygen
consumption, which subsequently results in a severe mis-
match of cardiac oxygen delivery versus oxygen consump-
tion (31). Another contributing factor to this mechanism
may be altered catecholamine receptor function. We have
observed that the effects of epinephrine during prolonged
CPR seemed to be more attenuated in comparison with
vasopressin (13,27,28). In fact, rodent artery models sub-
jected to metabolic acidosis showed selective blunting of
vasoconstrictor responses to norepinephrine, but not to
vasopressin (32). This may suggest that during prolonged
cardiac arrest, and therefore, global hypoxia and hypercarbic
acidosis, the pressor sensitivity to vasopressin may be nor-
mal, and the effects of catecholamines may be blunted (25).
Figure 1. Diastolic aortic pressure during CPR. Repeated doses of vasopressin (line with diamonds) but not epinephrine (line with
squares) or saline placebo (line with triangles) maintained the mean value 6SEM of aortic diastolic blood pressure above a threshold of
;30 to 40 mm Hg (horizontal dashed lines), which makes successful defibrillation likely. *p , 0.05 vs. epinephrine and saline placebo.
§p , 0.05 vs. saline placebo. ACLS 5 advanced cardiac life support; BLS 5 basic life support; DA 1 5 drug administration of 0.4 U/kg
vasopressin vs. 45 mg/kg epinephrine vs. saline placebo; DA 2 5 drug administration of 0.4 U/kg vasopressin vs. 45 mg/kg epinephrine
vs. saline placebo; DA 3 5 drug administration of 0.8 U/kg vasopressin vs. 200 mg/kg epinephrine vs. saline placebo. VF 5 ventricular
fibrillation. Time is given in minutes (9) and seconds (0).
Table 1. End-Tidal Carbon Dioxide Before Arrest and During Cardiopulmonary Resuscitation
Treatment
Before
Arrest
Cardiopulmonary Resuscitation (CPR)
90-s CPR
90 s After 5 min After 90 s After 5 min After 90 s After 5 min After
Drug Administration 1 Drug Administration 2 Drug Administration 3
Epinephrine 34 6 1 21 6 2 18 6 2 20 6 3 16 6 3 13 6 3 10 6 2 7 6 1
Vasopressin 35 6 1 22 6 0 21 6 2 14 6 1* 16 6 1 17 6 2 17 6 2† 17 6 2†
Saline placebo 37 6 1 25 6 2 24 6 2 24 6 3 23 6 2 20 6 3 15 6 2 14 6 4
*p , 0.05 vs. saline placebo. †p , 0.05 vs. epinephrine. Data are given as the mean value (mm Hg) 6SEM.
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Vasopressin during CPR improves vital organ blood
flow. Laboratory investigations revealed that vasopressin
given during CPR may result in cerebral blood flow that is
at or above brain perfusion levels during normal physiologic
conditions (12–14,28). In the present experiment, we doc-
umented that this enhanced brain perfusion during CPR
did not result in cerebral edema after successful resuscita-
tion. In fact, the vasopressin-treated animals moved their
legs within 60 min after return of spontaneous circulation
during mechanical ventilation, and subsequently had to be
sedated to ensure weaning from pharmacologic and venti-
latory support. This early sign of neurologic recovery is in
accordance with a clinical study, when a favorable coma
rating after successful resuscitation correlated significantly
with good neurologic outcome (33). Interestingly, several
complications in the postresuscitation phase such as cardiac
dysrhythmias, lung atelectasis or fever had to be treated, but
neurologic function was never endangered. For example,
one animal simply walked away from its endotracheal tube
in the weaning phase, but needed surface cooling for
increased body temperature. Another pig needed cardiover-
sion after return of spontaneous circulation, but interacted
with its environment amazingly rapidly after extubation.
After 24 h of return of spontaneous circulation, the only
neurologic deficit of all vasopressin-treated pigs was an
unsteady gait, which disappeared within another three days.
This observation confirms that in order to achieve full recovery
after cardiac arrest, both excellent management of advanced
cardiac life support and careful optimization of organ function
in the postresuscitation phase are of fundamental importance
(24).
If a drug is given during CPR followed by rapid defibril-
lation, return of spontaneous circulation could be attributed
to the beneficial effects of the drug or defibrillation, or both.
In the present model, we repeated drug administration
during 15 min of CPR three times on purpose to isolate the
drug-related effects, which may represent a useful tool to
determine the role of a pharmacological CPR intervention.
Full neurologic recovery in all animals at 24 or 48 h was
shown in comparable porcine CPR models using epineph-
rine when simulating 9 min (34) or 14 min (35) of no
flow–low blood flow versus 22 min of no flow–low blood
flow in our vasopressin-treated pigs.
MRI revealed no cerebral pathology in vasopressin-
treated pigs. Because neurodiagnostic tests such as evoked
potentials, electroencephalogram or positron emission to-
mography may not be able to accurately detect pathology
(36), we employed cerebral MRI imaging after successful
CPR. T2-weighted MRI allows the identification of cere-
bral pathology as early as after 8 h after an ischemic event
(37), permitting exact classification of the site and size of
cerebral pathology (38). Imaging was performed four days
after the experiment to ensure that cerebral ischemic regions
caused by extracellular edema would be fully developed.
Accordingly, the absence of cerebral cortical and subcortical
edema, intraparenchymal hemorrhage, ischemic brain le-
sions or cerebral infarction confirmed by T2-weighted MRI
indicates that the vasopressin-treated pigs fully recovered
from cardiac arrest both anatomically and physiologically.
As such, vasopressin during CPR may be a superior drug
as compared with epinephrine or saline placebo to ensure
both return of spontaneous circulation and favorable neu-
rologic outcome. Thus, if our results can be extrapolated to
clinical management of cardiac arrest, our study is in strong
disagreement with the current guidelines of both the Amer-
ican Heart Association (2) and the European Resuscitation
Council (3), which recommend repeated injection of epi-
nephrine during CPR if return of spontaneous circulation
cannot be achieved. However, only data from humans can
establish the clinical utility of vasopressin during cardiac
arrest. Accordingly, we have recently started a multicenter
clinical trial in Europe under the aegis of the European
Resuscitation Council to determine the role of vasopressin
versus epinephrine for the management of out-of-hospital
cardiac arrest victims.
Study limitations. Vasopressin receptors in pigs (lysine
vasopressin) and humans (arginine vasopressin) are differ-
Figure 2. Representative axial cerebral T2-weighted MRI (show-
ing occipital cortex and the basal ganglia) of a pig resuscitated with
vasopressin after 96 h of survival.
Figure 3. Representative coronary cerebral T2-weighted MRI
(showing parietal and temporal cortex and the basal ganglia) of a
pig resuscitated with vasopressin after 96 h of survival.
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ent, which may result in a different hemodynamic response
to exogenously administered arginine vasopressin. However,
the circulatory effects of arginine vasopressin, as adminis-
tered in the present investigation, may be even greater in
humans than in pigs. To minimize the risk of complications
due to infections or sepsis, or both, we decided to monitor
blood pressure with an arterial catheter only; therefore, we
were not able to measure vital organ blood flow or coronary
perfusion pressure during the experiment. We also used
young, healthy pigs that were free of atherosclerotic disease.
Furthermore, this study lacks dose-response data; therefore,
we are not able to report the minimally effective vasopressin
dose. Finally, we purposely omitted defibrillation attempts
on starting CPR and immediately after vasopressor to
determine the hemodynamic effects of the study drugs
during the resuscitation attempt.
Conclusions. During prolonged CPR, repeated vasopres-
sin administration, but not epinephrine or saline placebo,
ensured long-term survival with full neurologic recovery and
no cerebral pathology in this porcine CPR model.
APPENDIX: NEUROLOGICAL DEFICIT SCORE FOR PIGS (20)*
Level of Consciousness
0 5 Normal: complete awareness of auditory stimuli.
30 5 Clouded: conscious, but drowsy or irritable.
60 5 Stupor: motor response only to painful stimuli.
100 5 Coma: no motor response to painful stimuli.
Motor and Sensory Function
Motor response to pinch hoof-pad
0 5 Normal: brisk withdrawal.
10 5 Sluggish response.
25 5 Very sluggish response.
50 5 No response.
Muscle tone: pick up and release extremity
0 5 Normal tone.
25 5 One or two extremities stiff or flaccid.
50 5 Three or four extremities stiff or flaccid.
Respiratory Pattern
0 5 Normal.
50 5 Abnormal spontaneous breathing.
100 5 Apnea.
Behavior
Standing
0 5 Can stand.
20 5 Cannot stand.
Walking
0 5 Normal.
10 5 Unsteady gait.
20 5 Very unsteady or ataxic gait.
30 5 Cannot walk.
Restraint: attempt to hold down pig from behind
0 5 Normal: vigorously resists.
20 5 Sluggish; resists.
40 5 Very sluggish; resists minimally.
50 5 No resistance.
*Values are assigned for deficits in neurologic function; for example, a score of 0 is
normal and a score of 400 reflects brain death.
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